Multiplicom develops, manufactures and markets molecular diagnostic assays, which come in the form of kits, enabling personalised medicine. Following its founding in 2011 as a spin-off of UAntwerp and VIB, Multiplicom obtained its first CE-IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer susceptibility in late 2012. Multiplicom was the first company in Europe to be awarded this BRCA CE-IVD-certification and continues to develop high-quality ‘massively parallel sequencing (MPS)’-based assays.


+32 (0)3 289 14 00

Subscribe to our
mailing list

  • This field is for validation purposes and should be left unchanged.